The American Society of Dermatopathology

Special Topics

Essentials of Oncodermatopathology: Cutaneous Reactions to Novel Cancer Therapies and Beyond

Friday, November 6
8:00 a.m. - 12:30 p.m. Central Time

Course Director
Emily Y. Chu, MD, PhD
University of Pennsylvania

AMA PRA Category 1 CreditsTM

Advances in treatments for cancer with small molecule inhibitors (Nibs) and monoclonal antibodies (Mabs) have led to a diverse array of cutaneous adverse reactions. Dermatopathologic diagnosis of these cutaneous adverse reactions poses challenges due to the development of hundreds of novel, clinically available cancer agents and the continued emergence of new adverse reactions to these types of therapies. Knowledge of the range of cutaneous adverse reactions and accurate diagnosis is essential for optimal patient care. This course will present the spectrum of cutaneous adverse reactions to novel cancer therapies, including tyrosine kinase inhibitors and immunotherapy agents, among others. In addition, cutaneous manifestations of graft-versus-host disease, neutrophilic dermatoses, as well as opportunistic infections in the immune compromised cancer patient will be reviewed. Dermatopathologists should also gain familiarity with BRAF V600E and PD-L1 immunohistochemical biomarker evaluation used to stratify cancer patients for clinical trials and neoadjuvant therapy. Pitfalls and pearls in examination and reporting these biomarkers will be discussed. 

Faculty and Course Outline

8:00 a.m. - 8:05 a.m.                             Introduction
Emily Y. Chu, MD, PhD
University of Pennsylvania
8:05 a.m. - 8:35 a.m. Cutaneous infections in cancer patients
Dirk M. Elston, MD
Medical University of South Carolina
8:35 a.m. - 9:05 a.m.      Cutaneous Adverse Reactions to Vemurafenib and Other Nibs
Emily Y. Chu, MD, PhD
University of Pennsylvania
9:05 a.m. - 9:35 a.m. Cutaneous Adverse Reactions to Checkpoint Inhibitors and Other Mabs
Jonathan L. Curry, MD
University of Texas MD Anderson Cancer Center
9:35 a.m. - 10:05 a.m.  Clinical Implicatons of Cutaneous Adverse Reactions to Cancer Therapy
Jennifer N. Choi, MD
Northwestern University Feinberg School of Medicine
10:05 a.m. - 10:30 a.m.   Break
10:30 a.m. - 11:00 a.m.  Graft-versus-Host Disease
Julia S. Lehman, MD
Mayo Clinic, Rochester
11:00 a.m. - 11:30 a.m.  Neutrophilic Dermatoses
Marcela Saeb-Lima, MD
Instituto Nacional de Ciencias Medicas y NutriciĆ³n Salvador Zubiran
11:30 a.m. - 12:00 p.m. Dermatopathology Urgencies: When Pathology Comes to the Rescue
Farah Abdulla, MD
City of Hope
12:00 p.m. - 12:30 p.m. Q & A
 

Learning Objectives
Upon completion of this course, participants should be able to:

  • Identify common cutaneous adverse reactions associated with immunotherapy agents and tyrosine kinase inhibitors.
  • Discuss diagnostic features of neutrophilic dermatoses.
  • Recognize key features of opportunistic infections in cancer patients.